MS Research Update — July 17, 2026
Updated Thesis
Morgan Stanley is a leading global financial services firm specializing in capital markets, wealth management, and investment banking. The company demonstrates high business quality with a strong return on equity of 23.4% and robust revenue growth of 22.4% in the most recent quarter, alongside impressive earnings growth of 57.7% in the same period. Its gross margin of 56.6% and net margin of 20.2% reflect operational efficiency.
The investment grade as of this refresh is B — solid business quality. High-tier business, fair-tier valuation
Key Metrics at a Glance
- Revenue growth: +22.4% year over year
- Net margin: 20.2%
- Forward P/E: 23.6x
- Fair value upside: +45.0% to our estimate of $317
Current price: $218.37
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Morgan Stanley remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MS research →](/stocks/MS)